How much is a share of Zivo worth?
One share of ZIVO stock can currently be purchased for approximately $3.72. How much money does ZIVO Bioscience make? ZIVO Bioscience has a market capitalization of $35.04 million and generates $20 thousand in revenue each year.
Is Zivo Bioscience (Zio) a buy or sell?
ZIVO Bioscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings. According to analysts' consensus price target of $9.00, ZIVO Bioscience has a forecasted upside of 141.9% from its current price of $3.72.
What companies are related to Zivo?
Some companies that are related to ZIVO Bioscience include Innovator Laddered Fund of S&P 500 Power Buffer ETFs (BUFF), MeaTech 3D (MITC), Laird Superfood (LSF), TDH (PETZ), Stryve Foods (SNAX), Sow Good (SOWG) and New Earth Life Sciences (EFLI). View all of ZIVO's competitors.
Is Zovio a turnaround in the making?
“We're a turnaround in the making," he said. Zovio Inc (Nasdaq: ZVO), an education technology services company that partners with higher education institutions and employers, today announced, as required by Nasdaq Stock Market rules, the grant of inducement awards to its new CEO, Mr. Randy Hendricks on December 6, 2021.
Should I buy or sell ZIVO Bioscience stock right now?
1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ZIVO Bioscience in the last year. There are currently 1...
What is ZIVO Bioscience's stock price forecast for 2022?
1 Wall Street analysts have issued twelve-month price objectives for ZIVO Bioscience's stock. Their forecasts range from $9.00 to $9.00. On average...
How has ZIVO Bioscience's stock performed in 2022?
ZIVO Bioscience's stock was trading at $2.87 on January 1st, 2022. Since then, ZIVO shares have increased by 22.0% and is now trading at $3.50. Vi...
How were ZIVO Bioscience's earnings last quarter?
ZIVO Bioscience, Inc. (OTCMKTS:ZIVO) issued its earnings results on Monday, May, 11th. The biotechnology company reported ($0.01) EPS for the quart...
Who are ZIVO Bioscience's key executives?
ZIVO Bioscience's management team includes the following people: Mr. John B. Payne , Pres, CEO & Chairman (Age 74, Pay $39.55k) Mr. Keith R. Mar...
Who are some of ZIVO Bioscience's key competitors?
Some companies that are related to ZIVO Bioscience include Genenta Science (GNTA) , Big Cypress Acquisition (BCYP) , Gamida Cell (GMDA) , Jaspe...
What other stocks do shareholders of ZIVO Bioscience own?
Based on aggregate information from My MarketBeat watchlists, some companies that other ZIVO Bioscience investors own include Nabriva Therapeutics...
What is ZIVO Bioscience's stock symbol?
ZIVO Bioscience trades on the OTCMKTS under the ticker symbol "ZIVO."
Who are ZIVO Bioscience's major shareholders?
ZIVO Bioscience's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (0.9...
Is Zivo Bioscience stock a Buy, Sell or Hold?
Zivo Bioscience stock has received a consensus rating of buy. The average rating score is and is based on 1 buy ratings, 0 hold ratings, and 0 sell...
What was the 52-week low for Zivo Bioscience stock?
The low in the last 52 weeks of Zivo Bioscience stock was 2.37. According to the current price, Zivo Bioscience is 141.35% away from the 52-week low.
What was the 52-week high for Zivo Bioscience stock?
The high in the last 52 weeks of Zivo Bioscience stock was 7.90. According to the current price, Zivo Bioscience is 42.41% away from the 52-week high.
What are analysts forecasts for Zivo Bioscience stock?
The 1 analysts offering price forecasts for Zivo Bioscience have a median target of 9.00, with a high estimate of 9.00 and a low estimate of 9.00....
About ZIVO Bioscience
ZIVO Bioscience (OTCMKTS:ZIVO) Frequently Asked Questions
Zivo Bioscience, Inc. engages in the study, development, and commercialization of natural nutritional compounds and bioactive molecules. It offers proprietary algae strain, extracts and supernatants, and bioactive compounds. The company was founded by Howard R. Baer on March 28, 1983 and is headquartered in Keego Harbor, MI.
50 Biggest Movers From Yesterday
1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ZIVO Bioscience in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ZIVO Bioscience stock. View analyst ratings for ZIVO Bioscience or view top-rated stocks.
39 Stocks Moving In Wednesday's Mid-Day Session
Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares surged 105.1% to close at $14.79 on Wednesday after Oppenheimer initiated coverage on the stock with an Outperform rating and a $21 price target.
20 Stocks Moving in Wednesday's Pre-Market Session
Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares jumped 113% to $15.36 after Oppenheimer initiated coverage on the stock with an Outperform rating and a $21 price target.
48 Biggest Movers From Yesterday
Gainers Puxin Limited (NYSE: NEW) rose 52.1% to $0.6901 in pre-market trading after dipping 24% on Tuesday.
Signals & Forecast
Gainers Gogo Inc. (NASDAQ: GOGO) shares climbed 37.6% to close at $16.82 on Tuesday after the company raised the long-term financial targets announced during Q4 2020 earnings.
Support, Risk & Stop-loss
The Zivo Bioscience, Inc. stock holds a sell signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock.
Is Zivo Bioscience, Inc. stock A Buy?
Zivo Bioscience, Inc. finds support from accumulated volume at $3.50 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Insiders are very positive buying more shares than they are selling in Zivo Bioscience, Inc
Zivo Bioscience, Inc. holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
About Zivo Bioscience, Inc
In the last 100 trades there were 58.73 million shares bought and 6.31 million shares sold. The last trade was done 11 days ago by Maggiore Christopher D. who bough 44.97 thousand shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.
Golden Star Signal
ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
What is Zovio AOD?
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
What is Zovio in education?
Zovio, Inc. (Nasdaq: ZVO) an education technology services company that partners with higher education institutions, announced today it has agreed to resolve an in quiry by the Massachusetts Attorney General's Office through an Assurance of Discontinuance ("AOD"). Zovio cooperated fully with the Attorney General's inquiry, which focused on alleged violations of the Massachusetts consumer protection laws.
When is Zovio's fireside chat 2021?
Zovio (Nasdaq: ZVO), an education technology services company that works with higher education institutions and employers to deliver educational programming and benefits, has partnered with Munich Re, one of the world's leading providers of reinsurance, primary insurance, and insurance-related risk solutions, to provide debt-free education to their employees since 2019.
